Hypothesis: Senescent cell-derived extracellular vesicles reprogram NAD+ salvage pathway enzymes in neighboring cells, accelerating epigenetic age independently of local SASP cytokine signaling
Background
Senescent cells drive aging through the senescence-associated secretory phenotype (SASP), traditionally attributed to pro-inflammatory cytokines (IL-6, IL-8, TNF-α). However, senescent cells also release abundant extracellular vesicles (EVs) carrying miRNAs, proteins, and metabolites whose paracrine effects remain poorly characterized.
NAD+ decline is a hallmark of aging, driven partly by increased CD38 expression and decreased NAMPT activity. Epigenetic clocks (Horvath, GrimAge) capture methylation changes that correlate with biological age but whose upstream molecular triggers are incompletely mapped.
Hypothesis
I propose that senescent cell-derived EVs contain miR-34a and miR-29b cargo that directly downregulates NAMPT and NMNAT1 expression in recipient non-senescent cells, causing local NAD+ depletion. This NAD+ deficit impairs sirtuin-dependent maintenance of DNA methylation patterns (particularly SIRT1-mediated deacetylation of DNMT3B), leading to accelerated epigenetic clock progression in bystander cells — independent of classical SASP cytokine signaling.
Key Predictions
- EV-specific effect: Conditioned media from senescent cells depleted of EVs (by ultracentrifugation) but retaining soluble SASP factors will NOT accelerate epigenetic age in recipient fibroblasts, while purified EVs alone WILL.
- miRNA dependency: Knockout of miR-34a/miR-29b in senescent cells (or Dicer knockdown to block EV miRNA loading) will abolish the NAD+-depleting and epigenetic-aging effects of their EVs.
- NAD+ rescue: Co-treatment of recipient cells with NMN (bypassing NAMPT) will block EV-induced epigenetic acceleration despite continued EV exposure.
- In vivo: Senolytic treatment (dasatinib+quercetin) will reduce circulating EV-associated miR-34a levels and correlate with epigenetic age deceleration measured by blood-based clocks.
Proposed Test
Induce senescence in IMR-90 fibroblasts via ionizing radiation. Collect EVs vs. EV-depleted conditioned media. Treat young fibroblasts for 14 days. Measure: (a) NAMPT/NMNAT1 protein by Western blot, (b) NAD+/NADH ratio by enzymatic assay, (c) epigenetic age by Horvath clock on Illumina EPIC array, (d) SIRT1 activity and DNMT3B acetylation status.
Significance
If confirmed, this identifies a non-cytokine, EV-mediated mechanism linking cellular senescence to NAD+ decline and epigenetic aging — suggesting that senolytics may partly work by eliminating a source of aging-accelerating EVs, and that EV-filtering or miRNA-targeting therapies could be a complementary anti-aging strategy without requiring senescent cell killing.
Relevance to Autoimmune Disease
In rheumatic diseases (RA, SLE), premature senescence and accelerated epigenetic aging are well-documented. If senescent synovial fibroblast EVs drive NAD+ depletion in joint tissue, this could explain the accelerated biological aging seen in RA patients and suggest EV-targeted adjunct therapies.